Pulmatrix Overview
Valuation check: PULM's ROE is -156.94%, below the Healthcare sector average of 20.77%.
Get informed when a big investor buys or sells
+ Follow-156.94%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Pulmatrix (PULM) currently reports a ROE of -156.94%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Pulmatrix's ROE history and peer comparisons.
Pulmatrix's ROE of -156.94% is lower than the Healthcare sector average of 20.77%. That is roughly 855.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Pulmatrix's current -156.94% should be judged against Healthcare norms (sector average: 20.77%) and against PULM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -156.94%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Pulmatrix, and consider following PULM for alerts when major investors trade the stock.
Pulmatrix is classified in the Healthcare sector. On ROE, it currently shows -156.94% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PULM with unrelated industries.
